Macrogenics (MGNX)

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Company profile

Ticker

MGNX

Exchange

NASDAQ

Website

www.macrogenics.com

CEO

Scott Koenig

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

SEC CIK

0001125345

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

MGNX stock data

1M 1Y 5Y

News

From Benzinga Pro

What 5 Analyst Ratings Have To Say About Macrogenics

9 Aug 22

Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:

MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce

9 Aug 22

SVB Leerink Maintains Outperform on Macrogenics, Lowers Price Target to $12

9 Aug 22

SVB Leerink analyst Jonathan Chang maintains Macrogenics (NASDAQ:MGNX) with a Outperform and lowers the price target from $15 to $12.

Barclays Maintains Overweight on Macrogenics, Lowers Price Target to $8

9 Aug 22

Macrogenics: Q2 Earnings Insights

8 Aug 22

Press releases

From Benzinga Pro

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

8 Aug 22

First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by year-endInitiates cost-saving measures through corporate

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

25 Jul 22

ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

8 Jul 22

ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer,

MacroGenics to Participate in Upcoming Investor Conference

8 Jun 22

MacroGenics Announces Appointment of William Heiden to Board of Directors

23 May 22

Analyst ratings and price targets

Last 3 months

Average target

$11.00

Low target

$4.00

High target

$20.00

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

8 Aug 22

11 Aug 22

31 Dec 22

Financial summary

Financial statements Chart MGNX financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	21.47M	21.47M	21.47M	21.47M	21.47M	21.47M
Cash burn (monthly)	8.62M	13.96M	13.94M	18.31M	16.39M	14.66M
Cash used (since last report)	12.08M	19.57M	19.54M	25.66M	22.97M	20.55M
Cash remaining	9.39M	1.9M	1.93M	-4.19M	-1.5M	914.08K
Runway (months of cash)	1.1	0.1	0.1	-0.2	-0.1	0.1

Beta Read what these cash burn values mean

Financial data from Macrogenics earnings reports.

Recent insider trades

MGNX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jun 22	Karrels James	Common Stock	Buy	Acquire P	No	No	2.47	40,000	98.8K	191,776
23 May 22	William K Heiden	Stock Option Common Stock	Grant	Acquire A	No	No	3.96	36,000	142.56K	36,000
19 May 22	Siegel Jay Philip	Stock Option Common Stock	Grant	Acquire A	No	No	3.9	24,080	93.91K	24,080
19 May 22	Siegel Jay Philip	Stock Option Common Stock	Grant	Acquire A	No	No	3.9	18,000	70.2K	18,000
19 May 22	O'Brien Federica F.	Stock Option Common Stock	Grant	Acquire A	No	No	3.9	24,080	93.91K	24,080
19 May 22	O'Brien Federica F.	Stock Option Common Stock	Grant	Acquire A	No	No	3.9	18,000	70.2K	18,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

MGNX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	146	158	-7.6%
Opened positions	19	25	-24.0%
Closed positions	31	22	+40.9%
Increased positions	58	53	+9.4%
Reduced positions	39	48	-18.8%

13F shares	Current	Prev Q	Change
Total value	661.28M	2.32B	-71.5%
Total shares	68.16M	65.05M	+4.8%
Total puts	0	36.9K	EXIT
Total calls	35.5K	46.2K	-23.2%
Total put/call ratio	–	0.8	–

Largest owners	Shares	Value	Change
BLVGF Bellevue	7.33M	$64.54M	-14.4%
BBBOF BB Biotech	7.28M	$116.77M	0.0%
Ra Capital Management	6.1M	$53.77M	0.0%
BLK Blackrock	5.17M	$45.52M	-0.5%
Armistice Capital	5M	$44.05M	+85.2%
Wasatch Advisors	4.04M	$35.6M	-1.6%
Vanguard	4.03M	$35.52M	+2.2%
RTW Investments	3.98M	$35.03M	0.0%
STT State Street	3.54M	$31.23M	+21.7%
Perceptive Advisors	1.56M	$13.74M	-6.3%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	5M	+2.3M	+85.2%
Point72 Asset Management	0	-1.26M	EXIT
BLVGF Bellevue	7.33M	-1.23M	-14.4%
Assenagon Asset Management	1.25M	+1.08M	+618.9%
Great Point Partners	0	-1M	EXIT
STT State Street	3.54M	+632.05K	+21.7%
Renaissance Technologies	585.71K	+585.71K	NEW
Millennium Management	1.52M	+488.6K	+47.5%
FMR	873.69K	-376.79K	-30.1%
MS Morgan Stanley	613.11K	+367.15K	+149.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Regeneron Pharmaceuticals • Astrazeneca • Nektar Therapeutics • Seagen • Molecular Templates • Stemline Therapeutics • Xencor • SELLAS Life Sciences • Puma Biotechnology

Risks

If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.
The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval.
Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the crisis in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.

Management Discussion

We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators. These product candidates include multiple immuno-oncology programs, some of which were created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accrual, add, adequate, adequately, administered, arise, armed, attain, attract, boxed, breach, civil, Cohort, competing, comprehensive, conclusion, confidence, confirm, contraindication, costly, country, coupled, criminal, decide, decided, deny, deteriorate, dilutive, diminished, discretion, dysfunction, efficacy, endpoint, energy, experienced, extreme, fail, field, final, force, gastric, halt, harm, head, health, higher, highly, identification, import, imposition, inability, inconclusive, inflation, instability, interrupt, IRB, judicially, larger, left, lengthy, line, macroeconomic, MAHOGANY, mandatory, manner, midst, morale, neck, overseeing, past, patient, pembrolizumab, permitted, personnel, pharmaceutical, preliminary, prescribing, prevent, prevented, progressed, prolonged, promising, promote, prospective, publicly, published, qualification, recession, recruitment, recurrent, refusal, rely, renegotiate, repeat, reputation, restructuring, resubmit, safety, satisfaction, saving, SCCHN, scientific, secondary, show, side, Similarly, size, slowdown, smaller, spending, stability, stopped, suffer, suffered, suitable, suspended, suspension, TAMARACK, terrorist, therapy, threatened, top, toxicity, turn, unacceptable, uncommitted, undergo, undergone, undesirable, unemployment, unexpected, unforeseen, unplanned, unrest, vary, ventricular, verification, voluntary, war, warning, widespread, wind, withdrawal

Removed: begin, expansion, exposure

From filing 10-Q 2022 Q2

Financial reports

View all